Literature DB >> 20531237

Reduced hypocretin (orexin) levels in dementia with Lewy bodies.

Stephanie Lessig1, Kiren Ubhi, Douglas Galasko, Anthony Adame, Emiley Pham, Kelly Remidios, Michael Chang, Lawrence A Hansen, Eliezer Masliah.   

Abstract

Sleep disorders are observed in Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease; however, the underlying mechanisms are unclear. Reduced hypocretin (orexin) levels are reported in Parkinson's disease and sleep disorders, including narcolepsy; however, its levels in dementia with Lewy bodies and Alzheimer's disease and its relationship with sleep disturbances in these disorders remain undetermined. We examined hypocretin levels in dementia with Lewy bodies and Alzheimer's disease cases and correlated these with sleep habits and clinical characteristics. Although limited hypocretin alterations were observed in Alzheimer's disease, we show reduced neocortical hypocretin immunoreactivity in dementia with Lewy bodies patients correlating with hypersomnolence and alpha-synuclein levels. These results suggest the involvement of hypocretin in sleep disorders in dementia with Lewy bodies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20531237      PMCID: PMC2908368          DOI: 10.1097/WNR.0b013e32833bfb7c

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  23 in total

Review 1.  Pathoanatomy of Parkinson's disease.

Authors:  H Braak; E Braak
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

Review 2.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

3.  HLA class II genes associated with REM sleep behavior disorder.

Authors:  C H Schenck; E Garcia-Rill; M Segall; H Noreen; M W Mahowald
Journal:  Ann Neurol       Date:  1996-02       Impact factor: 10.422

Review 4.  REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions.

Authors:  Bradley F Boeve
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

5.  The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.

Authors:  L de Lecea; T S Kilduff; C Peyron; X Gao; P E Foye; P E Danielson; C Fukuhara; E L Battenberg; V T Gautvik; F S Bartlett; W N Frankel; A N van den Pol; F E Bloom; K M Gautvik; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

6.  Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

Authors:  T Sakurai; A Amemiya; M Ishii; I Matsuzaki; R M Chemelli; H Tanaka; S C Williams; J A Richardson; G P Kozlowski; S Wilson; J R Arch; R E Buckingham; A C Haynes; S A Carr; R S Annan; D E McNulty; W S Liu; J A Terrett; N A Elshourbagy; D J Bergsma; M Yanagisawa
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

7.  Low levels of ventricular CSF orexin/hypocretin in advanced PD.

Authors:  X Drouot; S Moutereau; J P Nguyen; J P Lefaucheur; A Créange; P Remy; F Goldenberg; M P d'Ortho
Journal:  Neurology       Date:  2003-08-26       Impact factor: 9.910

Review 8.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

9.  Relationship between CSF hypocretin levels and hypocretin neuronal loss.

Authors:  Dmitry Gerashchenko; Eric Murillo-Rodriguez; Ling Lin; Man Xu; Laura Hallett; Seiji Nishino; Emmanuel Mignot; Priyattam J Shiromani
Journal:  Exp Neurol       Date:  2003-12       Impact factor: 5.330

10.  Entorhinal neurofibrillary tangles in Alzheimer disease with Lewy bodies.

Authors:  L A Hansen; E Masliah; S Quijada-Fawcett; D Rexin
Journal:  Neurosci Lett       Date:  1991-08-19       Impact factor: 3.046

View more
  10 in total

1.  Sleep Disorders in Atypical Parkinsonism.

Authors:  Sabra M Abbott; Aleksandar Videnovic
Journal:  Mov Disord Clin Pract       Date:  2014-06-01

Review 2.  Sleep disturbances in Alzheimer's and Parkinson's diseases.

Authors:  Sarah M Rothman; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2012-05-03       Impact factor: 3.843

Review 3.  Pharmacological Management of Apathy in Dementia.

Authors:  Laiba Azhar; Raphael W Kusumo; Giovanni Marotta; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2022-01-10       Impact factor: 5.749

Review 4.  RBD and Neurodegenerative Diseases.

Authors:  Haiyang Jiang; Jinsha Huang; Yan Shen; Shiyi Guo; Luxi Wang; Chao Han; Ling Liu; Kai Ma; Yun Xia; Jie Li; Xiaoyun Xu; Nian Xiong; Tao Wang
Journal:  Mol Neurobiol       Date:  2016-03-31       Impact factor: 5.590

5.  Wake-active neurons across aging and neurodegeneration: a potential role for sleep disturbances in promoting disease.

Authors:  Anna L Stern; Nirinjini Naidoo
Journal:  Springerplus       Date:  2015-01-17

6.  Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer's disease using the Multiple Sleep Latency Test.

Authors:  Tanis J Ferman; Glenn E Smith; Dennis W Dickson; Neill R Graff-Radford; Siong-Chi Lin; Zbigniew Wszolek; Jay A Van Gerpen; Ryan Uitti; David S Knopman; Ronald C Petersen; Joseph E Parisi; Michael H Silber; Bradley F Boeve
Journal:  Alzheimers Res Ther       Date:  2014-12-10       Impact factor: 6.982

7.  Sleep in Alzheimer's Disease - Beyond Amyloid.

Authors:  Jerrah Holth; Tirth Patel; David M Holtzman
Journal:  Neurobiol Sleep Circadian Rhythms       Date:  2016-08-10

8.  Serotonergic dysregulation is linked to sleep problems in Parkinson's disease.

Authors:  Heather Wilson; Beniamino Giordano; Federico E Turkheimer; Kallol Ray Chaudhuri; Marios Politis
Journal:  Neuroimage Clin       Date:  2018-03-02       Impact factor: 4.881

9.  Orexin-A in Patients With Lewy Body Disease: A Systematic Review and Meta-Analysis.

Authors:  Jinghuan Gan; Zhichao Chen; Jiuyan Han; Lingyun Ma; Shuai Liu; Xiao-Dan Wang; Yong Ji
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-17       Impact factor: 5.555

10.  Cerebrospinal fluid melanin-concentrating hormone (MCH) and hypocretin-1 (HCRT-1, orexin-A) in Alzheimer's disease.

Authors:  Frank M Schmidt; Juergen Kratzsch; Hermann-Josef Gertz; Mandy Tittmann; Ina Jahn; Uta-Carolin Pietsch; Udo X Kaisers; Joachim Thiery; Ulrich Hegerl; Peter Schönknecht
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.